BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/12/2026 6:20:01 AM | Browse: 1 | Download: 1
 |
Received |
|
2026-03-24 01:57 |
|
Peer-Review Started |
|
2026-03-24 01:57 |
|
First Decision by Editorial Office Director |
|
2026-04-03 04:59 |
|
Return for Revision |
|
2026-04-03 07:23 |
|
Revised |
|
2026-04-13 19:05 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-06-01 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-06-01 09:55 |
|
Articles in Press |
|
2026-06-01 09:55 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-08 02:55 |
|
Publish the Manuscript Online |
|
2026-06-12 06:20 |
| ISSN |
2308-3840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Molecular targets of ivermectin as a potential repurposed drug in cancer therapy: A scoping review
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Roy Olunga, Walter Jaoko, Reinhard Kipkoech, Gloria Natalia, Ruth J Tai, Lydia Mutanu, Moses Jengo, Faith W Mwangi, Olivia Ayuma and Udochukwu G Anosike |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Roy Olunga, Department of Clinical Medicine and Therapeutics, University of Nairobi, Ngong Road, Nairobi 00100, Nairobi City, Kenya. royolunga71@gmail.com |
| Key Words |
Ivermectin; Cancer; Ivermectin-drug interactions; Drug repurposing; Molecular targets |
| Core Tip |
Ivermectin shows promise as a repurposed anticancer agent by targeting multiple molecular pathways, including inhibition of Wnt/β-catenin signaling, modulation of p21-activated kinase 1 activity, and induction of mitochondrial dysfunction. Its ability to induce apoptosis, suppress tumor growth, and overcome drug resistance highlights its therapeutic potential across diverse cancer types. Available clinical evidence is preliminary and requires rigorous clinical validation to establish safety, efficacy, and optimal dosing in oncology. Ivermectin’s multitargeted mechanisms make it a possible candidate for cancer therapy, but translation into clinical practice demands cautious, evidence-based evaluation through well-designed clinical trials. |
| Publish Date |
2026-06-12 06:20 |
| Citation |
Olunga R, Jaoko W, Kipkoech R, Natalia G, Tai RJ, Mutanu L, Jengo M, Mwangi FW, Ayuma O, Anosike UG. Molecular targets of ivermectin as a potential repurposed drug in cancer therapy: A scoping review. World J Meta-Anal 2026; 14(2): 121391
|
| URL |
https://www.wjgnet.com/2308-3840/full/v14/i2/121391.htm |
| DOI |
https://doi.org/10.13105/wjma.v14.i2.121391 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
